secwatch.observer — SEC 8-K summary
======================================

Issuer:     First Tracks Biotherapeutics, Inc. (TRAX)
CIK:        0002091349
Form:       8-K
Filed at:   2026-10-15T20:28:55+00:00
Accession:  0001193125-26-422929
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

First Tracks Biotherapeutics raises $200M in private placement at $32.75/share
------------------------------------------------------------------------------

- Sells 6,106,870 common shares at $32.75/share for ~$200M gross proceeds; closing expected October 19, 2026, subject to customary conditions.
- Investors include Affinity Asset Advisors, First Light Asset Management, Sirenia Capital, TCGX, Trails Edge Capital, Vestal Point Capital and mutual funds.
- Proceeds intended for general corporate purposes, including clinical development of ANB033, a CD122 antagonist.
- Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities acted as placement agents.
- Shares issued under Section 4(a)(2); resale registration statement due within 30 days of closing. 35,909,814 shares outstanding as of Oct 12, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2091349/000119312526422929/0001193125-26-422929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2091349/000119312526422929/trax-20261015.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-422929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer